Colin Bristow
Stock Analyst at UBS
(1.18)
# 3,451
Out of 4,711 analysts
86
Total ratings
30.77%
Success rate
-10.02%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colin Bristow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PTCT PTC Therapeutics | Maintains: Buy | $47 → $71 | $46.24 | +53.55% | 3 | Dec 3, 2024 | |
| GILD Gilead Sciences | Maintains: Neutral | $70 → $96 | $92.57 | +3.71% | 3 | Nov 21, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $562 → $586 | $397.27 | +47.51% | 13 | Nov 5, 2024 | |
| AMGN Amgen | Maintains: Neutral | $335 → $326 | $263.38 | +23.78% | 7 | Oct 31, 2024 | |
| MRK Merck & Co. | Maintains: Buy | $142 → $136 | $98.05 | +38.70% | 5 | Oct 9, 2024 | |
| BIIB Biogen | Maintains: Neutral | $234 → $202 | $146.47 | +37.91% | 10 | Oct 3, 2024 | |
| ALXO ALX Oncology Holdings | Maintains: Buy | $25 → $4 | $1.62 | +146.91% | 4 | Aug 16, 2024 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $14 → $6 | $1.85 | +224.32% | 3 | Aug 15, 2024 | |
| IMVT Immunovant | Maintains: Buy | $42 → $41 | $25.86 | +58.55% | 5 | Aug 13, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $3.5 → $1 | $0.34 | +193.26% | 5 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $31 | $26.36 | +17.60% | 8 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,090 → $1,099 | $701.85 | +56.59% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $5.83 | +534.65% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $56 → $54 | $11.56 | +367.13% | 2 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $164 → $167 | $118.97 | +40.37% | 5 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $428 → $420 | $767.76 | -45.30% | 1 | Dec 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $12 → $2 | $10.31 | -80.60% | 2 | Dec 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.51 | +1,092.05% | 1 | Oct 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $154 → $146 | $175.58 | -16.85% | 2 | Aug 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $73 → $75 | $57.33 | +30.82% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $64 → $26 | $3.95 | +558.23% | 1 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $8.75 | +2.86% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $195 | $0.16 | +121,775.00% | 2 | Feb 1, 2021 |
PTC Therapeutics
Dec 3, 2024
Maintains: Buy
Price Target: $47 → $71
Current: $46.24
Upside: +53.55%
Gilead Sciences
Nov 21, 2024
Maintains: Neutral
Price Target: $70 → $96
Current: $92.57
Upside: +3.71%
Vertex Pharmaceuticals
Nov 5, 2024
Maintains: Buy
Price Target: $562 → $586
Current: $397.27
Upside: +47.51%
Amgen
Oct 31, 2024
Maintains: Neutral
Price Target: $335 → $326
Current: $263.38
Upside: +23.78%
Merck & Co.
Oct 9, 2024
Maintains: Buy
Price Target: $142 → $136
Current: $98.05
Upside: +38.70%
Biogen
Oct 3, 2024
Maintains: Neutral
Price Target: $234 → $202
Current: $146.47
Upside: +37.91%
ALX Oncology Holdings
Aug 16, 2024
Maintains: Buy
Price Target: $25 → $4
Current: $1.62
Upside: +146.91%
Acumen Pharmaceuticals
Aug 15, 2024
Maintains: Buy
Price Target: $14 → $6
Current: $1.85
Upside: +224.32%
Immunovant
Aug 13, 2024
Maintains: Buy
Price Target: $42 → $41
Current: $25.86
Upside: +58.55%
BioXcel Therapeutics
Aug 9, 2024
Maintains: Neutral
Price Target: $3.5 → $1
Current: $0.34
Upside: +193.26%
Jul 31, 2024
Maintains: Neutral
Price Target: $30 → $31
Current: $26.36
Upside: +17.60%
Apr 17, 2024
Maintains: Buy
Price Target: $1,090 → $1,099
Current: $701.85
Upside: +56.59%
Mar 28, 2024
Initiates: Buy
Price Target: $37
Current: $5.83
Upside: +534.65%
Mar 1, 2024
Maintains: Buy
Price Target: $56 → $54
Current: $11.56
Upside: +367.13%
Mar 1, 2024
Maintains: Buy
Price Target: $164 → $167
Current: $118.97
Upside: +40.37%
Dec 15, 2022
Maintains: Buy
Price Target: $428 → $420
Current: $767.76
Upside: -45.30%
Dec 8, 2022
Downgrades: Neutral
Price Target: $12 → $2
Current: $10.31
Upside: -80.60%
Oct 18, 2022
Initiates: Buy
Price Target: $18
Current: $1.51
Upside: +1,092.05%
Aug 1, 2022
Maintains: Neutral
Price Target: $154 → $146
Current: $175.58
Upside: -16.85%
Jul 28, 2022
Maintains: Neutral
Price Target: $73 → $75
Current: $57.33
Upside: +30.82%
Apr 18, 2022
Maintains: Buy
Price Target: $64 → $26
Current: $3.95
Upside: +558.23%
Aug 23, 2021
Initiates: Buy
Price Target: $9
Current: $8.75
Upside: +2.86%
Feb 1, 2021
Initiates: Neutral
Price Target: $195
Current: $0.16
Upside: +121,775.00%